Rocket Lab: The Market Is Pricing Ambition at a Steep Discount
Published on 07/25/2026 at 16:13 | Redaktion boerse-global.de
The numbers coming out of Rocket Lab these days tell two completely different stories. On one hand, the company is stacking wins: a $266 million defense contract for suborbital launches, a transformative $8 billion Iridium acquisition, and a new rocket engine that just passed a critical test. On the other, the stock has been gutted. Shares closed Friday at €56.40, down 8.29 percent on the day and nearly a quarter lower over the past month. From the 52-week high of €133.80 set on May 27, the decline now stands at almost 58 percent.
That kind of divergence between corporate momentum and market reception demands an explanation. The answer is more nuanced than a simple vote of no confidence.
A Sector-Wide Reckoning, Not Just a Rocket Lab Problem
Piper Sandler analyst Alexander Potter lit a fuse this week when he initiated coverage on both Rocket Lab and rival AST SpaceMobile, handing the latter a clear preference. Rocket Lab received only a "Neutral" rating, with Potter pointing to a more attractive valuation at the competitor. Both stocks sold off sharply on Thursday, and the damage carried into Friday.
The broader space sector has been bleeding in tandem. This looks less like a Rocket Lab-specific crisis and more like a rotation — investors rebalancing away from premium-priced space names as newer, well-capitalized entrants compete for attention and capital. That distinction matters. A sector-wide repricing is fundamentally different from a company failing to execute, but it hurts shareholders just the same.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The Iridium Deal: Vision Meets Valuation
The centerpiece of Rocket Lab's ambition is the Iridium acquisition, announced in late June at $54 per Iridium share in a cash-and-stock mix. The enterprise value of roughly $8 billion would create a vertically integrated space conglomerate — one that designs, builds, launches, and operates its own satellite constellations.
The market is struggling to price that vision. Rocket Lab's valuation remains elevated by traditional metrics, and the company has yet to demonstrate reliable profitability in its core business. The deal still requires shareholder and regulatory approvals, and integration risks loom precisely when Rocket Lab is also burning cash on its next-generation rocket. The pitch is compelling, but the execution timeline is long and the margin for error is thin.
Neutron: The Real Catalyst Is Still in Development
Beneath the Iridium noise lies an even bigger bet: Neutron, the partially reusable medium-lift rocket designed to challenge SpaceX's Falcon 9. The backlog is filling — five firm commercial missions are already booked ahead of the first flight — but public hardware updates have been scarce since January. CEO Peter Beck has pointed to the test stands as the key indicator, and the market is watching the schedule obsessively.
A recent milestone offers some reassurance: Rocket Lab completed a full-duration hot-fire test of the vacuum-optimized AVac engine, a critical step before the maiden flight targeted for the fourth quarter of 2026. But an engine test reduces technical uncertainty on propulsion alone. It doesn't answer questions about total program cost, schedule reliability, or future customer demand. And with VICTUS-HAZE follow-on missions, Iridium integration, and Neutron development all competing for capital, the risk of future dilution is real.
Technical Damage That Can't Be Ignored
The chart tells a story of exhaustion. The stock now trades roughly 37 percent below its 50-day moving average and has fallen under the 200-day line at €67.36 — a break that signals more than a temporary dip. The 14-day relative strength index sits at 30.8, flirting with oversold territory, while annualized 30-day volatility of roughly 88 percent underscores how violently sentiment can swing in either direction.
A stock trading below all major moving averages is, by the textbook, in a bearish posture. Oversold conditions can spark sharp recovery rallies, but with a name this volatile, they can also persist for weeks without a clear catalyst to reverse the mood.
The Analyst Consensus: Hope on Paper
Seventeen analysts have a consensus price target of €114.33, implying roughly 78 percent upside from current levels. That number is tantalizing, but it likely hasn't fully incorporated the latest selloff, and it assumes Neutron development stays on schedule. Until that rocket actually sits on the launch pad, any price target deserves skepticism.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
The average target of €100.53 cited elsewhere tells a similar story: the long-term thesis among analysts remains intact, even as short-term indicators flash oversold. The question is whether the market has the patience to wait for Neutron's first flight, the Iridium deal to close, and the earnings report due August 10 — any of which could shift the narrative.
What Comes Next
Rocket Lab is piling ambition on top of ambition: a transformative acquisition, an unproven medium-lift rocket, and a defense business winning contracts. The stock is pricing that ambition at a steep discount, and the gap between operational reality and market sentiment has rarely been wider.
For now, this is a news-driven trade for patient, risk-tolerant investors — not a steady compounder for those seeking stability. The next few weeks, whether shaped by earnings, a Neutron hardware milestone, or Iridium deal details, will determine whether this story resolves to the upside or continues to unravel. With volatility this high, the answer won't be quiet.
Ad
Rocket Lab Stock: New Analysis - 25 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
